Phase 3 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People who have been diagnosed with HER2-positive breast cancer that cannot be surgically removed or has spread to other parts of the body, and who have previously been treated with the medicines trastuzumab and taxane
- People whose general health and ability to carry out daily activities is rated as 0 or 1 on a standard medical scale (meaning fully active or restricted only in physically strenuous activity)
- People who have at least one tumour that can be measured using standard imaging methods
- People whose expected survival is at least 12 weeks
- People who are willing to give written consent to take part in the study
Who may not be able to join:
- People who have previously received a specific type of cancer treatment called an anti-HER2 antibody-drug conjugate (ADC) (confirm with trial site)
- People with a history of certain lung conditions — specifically interstitial lung disease, non-infectious pneumonitis, or radiation-related lung inflammation — that required treatment with steroids
- People with a known serious allergic reaction to the study drug's active or inactive ingredients, or to similar antibody-based medicines
- People who have had more than one type of cancer in the past 3 years, with some exceptions such as certain skin cancers, fully treated non-spreading tumours, or cancer in the opposite breast
- People with ongoing uncontrolled infections, certain autoimmune conditions requiring treatment, uncontrolled diabetes, uncontrolled high blood pressure, or other ongoing health conditions that may make it difficult to follow the study procedures
- People who are still experiencing side effects from previous cancer treatments that have not returned to a mild level or to their pre-treatment state (hair loss is an exception to this rule)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zefei Jiang, M.D., The Fifth Medical Center of the Chinese People's Liberation Army General Hospital
Phone: +86 13801896162
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.